Core Viewpoint - CNS Pharmaceuticals, Inc. has appointed Rami Levin as the new President and Chief Executive Officer, succeeding John Climaco, indicating a leadership change aimed at enhancing the company's strategic direction in biopharmaceuticals focused on cancer treatments [1] Group 1: Leadership Change - John Climaco has stepped down as Chief Executive Officer of CNS Pharmaceuticals [1] - Rami Levin, MBA, has been appointed as the new President and Chief Executive Officer [1] Group 2: Executive Background - Rami Levin brings nearly 30 years of global leadership experience in various medical fields including oncology, neurology, rare diseases, endocrinology, and cell and gene therapy [1] - Levin has a proven track record of scaling organizations and advancing late-stage clinical programs [1] - His experience includes driving transformative value creation within the biopharmaceutical sector [1]

Core Insights - CNS Pharmaceuticals, Inc. is focused on advancing next-generation anti-cancer therapies that are engineered to cross the blood-brain barrier, potentially improving efficacy for patients [1] - The lead program, TPI 287, is progressing towards a Phase 2 study for the treatment of glioblastoma multiforme (GBM), a highly aggressive brain cancer with a median survival of approximately 15 months from diagnosis [1] - The company expects its cash reserves to fund operations into the second half of 2026, indicating a stable financial position for ongoing research and development [1] Financial Performance - CNS Pharmaceuticals reported its financial results for the third quarter ended September 30, 2025, highlighting its commitment to developing treatments for brain and central nervous system cancers [1] - The company is entering the final quarter of the year with a focus on delivering meaningful developments for patients battling these cancers [1]

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - FGI Industries Ltd. (FGI) is up 278% at $15.02 [3] - Senmiao Technology Limited (AIHS) is up 96% at $4.22 [3] - Conifer Holdings, Inc. (CNFR) is up 86% at $2.11 [3] - WEBTOON Entertainment Inc. (WBTN) is up 39% at $20.81 [3] - Nukkleus Inc. (NUKK) is up 18% at $6.08 [3] - Tantech Holdings Ltd (TANH) is up 12% at $2.13 [3] - Check-Cap Ltd. (CHEK) is up 9% at $2.33 [3] - Ivanhoe Electric Inc. (IE) is up 8% at $9.71 [3] - Wolfspeed, Inc. (WOLF) is up 8% at $3.21 [3] - Bolt Projects Holdings, Inc. (BSLK) is up 5% at $3.95 [3] Premarket Losers - Envirotech Vehicles, Inc. (EVTV) is down 17% at $2.27 [4] - Dave & Buster's Entertainment, Inc. (PLAY) is down 15% at $20.40 [4] - NanoVibronix, Inc. (NAOV) is down 12% at $9.37 [4] - ADTRAN Holdings, Inc. (ADTN) is down 10% at $9.37 [4] - Rain Enhancement Technologies Holdco, Inc. (RAIN) is down 10% at $6.00 [4] - CNS Pharmaceuticals, Inc. (CNSP) is down 7% at $8.50 [4] - AVITA Medical, Inc. (RCEL) is down 7% at $6.22 [4] - Vince Holding Corp. (VNCE) is down 7% at $2.60 [4] - Monte Rosa Therapeutics, Inc. (GLUE) is down 6% at $6.50 [4] - Meiwu Technology Company Limited (WNW) is down 6% at $2.06 [4]

Group 1 - Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a price target of $20 [1] - The company is focusing on its oncology asset TPI-287, which is a blood-brain barrier crossing taxane in development for recurrent glioblastoma [1] - CNS Pharma's roadmap for TPI-287, along with a potential path forward with Berubicin and cash runway extending into the second half of 2026, positions the stock for recovery [1]